^
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive
:
A1
Merck (MSD) Press Release - 6d
HER-2 overexpression + PTEN deletion
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Resistant
:
C3
Sci Rep - 2wk
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive
:
A1
FDA - 3wk
FGFR2b overexpression + HER2 negative
Gastroesophageal Junction Adenocarcinoma
FPA-144
Sensitive
:
B
Amgen Press Release - 3wk
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive
:
A1
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Trazimera (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ontruzant (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ogivri (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Kanjinti (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Herzuma (trastuzumab biosimilar)
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
trifluridine/tipiracil
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
ramucirumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Ontruzant (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Kanjinti (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Ogivri (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
cisplatin + capecitabine
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
DOF
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
TCF
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
FP
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
CaT
Sensitive
:
A2
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
CAPOX
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our